e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Emerging strategies for airway disease treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Inhibition of MAP3K19 - A novel therapeutic approach for treatment of IPF
Stefen Boehme (San Diego, United States of America), Stefen Boehme, Tai Wei Ly, Kevin Bacon
Source:
International Congress 2015 – Emerging strategies for airway disease treatments
Session:
Emerging strategies for airway disease treatments
Session type:
Thematic Poster Session
Number:
4374
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Stefen Boehme (San Diego, United States of America), Stefen Boehme, Tai Wei Ly, Kevin Bacon. LATE-BREAKING ABSTRACT: Inhibition of MAP3K19 - A novel therapeutic approach for treatment of IPF. Eur Respir J 2015; 46: Suppl. 59, 4374
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015
LATE-BREAKING ABSTRACT: Molecular imaging with CXCR4-gallium-68-pentixafor PET correlates with GAP index and treatment effects in idiopathic pulmonary fibrosis
Source: International Congress 2016 – Mixed-up imaging of various chest diseases
Year: 2016
LATE-BREAKING ABSTRACT: DS102: A bioactive lipid for the treatment of chronic pulmonary disorders
Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease
Year: 2016
LATE-BREAKING ABSTRACT: Fibroblast conditioned matrix: A new approach to study extracellular matrix (ECM) effects in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – Repair pathways: from lung development to ageing of the lung
Year: 2016
LATE-BREAKING ABSTRACT: Antiacid therapy and progression free survival in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015
LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Idiopathic pulmonary fibrosis (IPF): epidemiology, biology, diagnosis and treatment
Source: Virtual Congress 2020 – When the lung gets stiff
Year: 2020
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery
Source: Eur Respir Rev 2013; 22: 148-152
Year: 2013
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Source: International Congress 2016 – IPF treatment II
Year: 2016
LATE-BREAKING ABSTRACT: Safety and tolerability of N-acetylcysteine (NAC) with pirfenidone in idiopathic pulmonary fibrosis (IPF): PANORAMA
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
Source: Eur Respir J 2007; 30: 835-839
Year: 2007
LATE-BREAKING ABSTRACT: Reducing inflammation in the lung by targeting the endothelial cystic fibrosis transmembrane conductance regulator with copper-tobramycin
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014
LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Idiopathic pulmonary fibrosis: approaches to diagnostic
Source: Eur Respir J 2002; 20: Suppl. 38, 61s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept